Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 30/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

57%

4 trials in Phase 3/4

Results Transparency

67%

4 of 6 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 4

2(28.6%)

Phase 3

2(28.6%)

N/A

2(28.6%)

Phase 2

1(14.3%)

7Total

Phase 4(2)

Phase 3(2)

N/A(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT04948307Not ApplicableCompleted

OXD01 in Combination With Sublingual Buprenorphine/Naloxone for Treatment of Opioid Use Disorder

Role: lead

NCT02243670Not ApplicableCompleted

Using Artificial Intelligence To Monitor Medication Adherence in Opioid Replacement Therapy

Role: collaborator

NCT01848054Phase 3Completed

Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Dependence

Role: lead

NCT01908842Phase 3Completed

Efficacy of BNX Sublingual Tablets Versus BNX Sublingual Film for Treatment of Opioid-Dependent Adults

Role: lead

NCT01315886Phase 4Terminated

Conversion From Fast Acting Oral Opioids to Abstral®

Role: lead

NCT01903005Phase 4Completed

Multi-Center, Open-Label, 24-Week Study of OX219 Safety and Efficacy for Maintenance Treatment of Opioid Dependence

Role: lead

NCT00758446Phase 2Completed

Efficacy and Safety Study of BLX-028914 in Subjects With Allergic Rhinitis

Role: collaborator

All 7 trials loaded